Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-286-084
Authors: W Carl Kester
Published by: Harvard Business Publishing
Originally published in: 1986
Version: 23 November 1992

Abstract

This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of issues concerning the ability of a multinational company to lower its cost of capital by tapping different capital markets worldwide.
Locations:
Size:
USD300 million sales
Other setting(s):
1981

About

Abstract

This small but rapidly growing Danish biochemical company must choose among several financing opportunities that include a convertible Eurobond, a rights offering in Denmark and an issue of new common shares in the United States. The case involves a broad range of issues concerning the ability of a multinational company to lower its cost of capital by tapping different capital markets worldwide.

Settings

Locations:
Size:
USD300 million sales
Other setting(s):
1981

Related